-
2
-
-
79959838081
-
Integrated genomic analyses of ovarian carcinoma
-
TCGA
-
TCGA Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
-
(2011)
Nature
, vol.474
, pp. 609-615
-
-
-
3
-
-
0037454224
-
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma
-
G. Singer, R. Oldt, Y. Cohen, B.G. Wang, D. Sidransky, and R.J. Kurman Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J Natl Cancer Inst 95 2003 484 486
-
(2003)
J Natl Cancer Inst
, vol.95
, pp. 484-486
-
-
Singer, G.1
Oldt, R.2
Cohen, Y.3
Wang, B.G.4
Sidransky, D.5
Kurman, R.J.6
-
4
-
-
65449169621
-
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay
-
V. Auner, G. Kriegshauser, D. Tong, R. Horvat, A. Reinthaller, and A. Mustea KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay BMC Cancer 9 2009 111
-
(2009)
BMC Cancer
, vol.9
, pp. 111
-
-
Auner, V.1
Kriegshauser, G.2
Tong, D.3
Horvat, R.4
Reinthaller, A.5
Mustea, A.6
-
5
-
-
67649440886
-
The biology of ovarian cancer: New opportunities for translation
-
R.C. Bast Jr., B. Hennessy, and G.B. Mills The biology of ovarian cancer: new opportunities for translation Nat Rev Cancer 9 2009 415 428
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 415-428
-
-
Bast, Jr.R.C.1
Hennessy, B.2
Mills, G.B.3
-
6
-
-
79960716001
-
Akt signalling in health and disease
-
I. Hers, E.E. Vincent, and J.M. Tavare Akt signalling in health and disease Cell Signal 23 2011 1515 1527
-
(2011)
Cell Signal
, vol.23
, pp. 1515-1527
-
-
Hers, I.1
Vincent, E.E.2
Tavare, J.M.3
-
7
-
-
0242637318
-
MTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF
-
K.M. Hannan, Y. Brandenburger, A. Jenkins, K. Sharkey, A. Cavanaugh, and L. Rothblum MTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF Mol Cell Biol 23 2003 8862 8877
-
(2003)
Mol Cell Biol
, vol.23
, pp. 8862-8877
-
-
Hannan, K.M.1
Brandenburger, Y.2
Jenkins, A.3
Sharkey, K.4
Cavanaugh, A.5
Rothblum, L.6
-
8
-
-
32044465506
-
TOR signaling in growth and metabolism
-
S. Wullschleger, R. Loewith, and M.N. Hall TOR signaling in growth and metabolism Cell 124 2006 471 484
-
(2006)
Cell
, vol.124
, pp. 471-484
-
-
Wullschleger, S.1
Loewith, R.2
Hall, M.N.3
-
10
-
-
38949183695
-
Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy
-
B.B. Friday, and A.A. Adjei Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy Clin Cancer Res 14 2008 342 346
-
(2008)
Clin Cancer Res
, vol.14
, pp. 342-346
-
-
Friday, B.B.1
Adjei, A.A.2
-
11
-
-
79951928689
-
Novel mitogen-activated protein kinase kinase inhibitors
-
M.S. Chapman, and J.N. Miner Novel mitogen-activated protein kinase kinase inhibitors Expert Opin Investig Drugs 20 2011 209 220
-
(2011)
Expert Opin Investig Drugs
, vol.20
, pp. 209-220
-
-
Chapman, M.S.1
Miner, J.N.2
-
12
-
-
84861515834
-
Targeting PI3Kinase/AKT/mTOR signaling in cancer
-
K.E. Sheppard, K.M. Kinross, B. Solomon, R.B. Pearson, and W.A. Phillips Targeting PI3Kinase/AKT/mTOR signaling in cancer Crit Rev Oncog 17 2012 69 95
-
(2012)
Crit Rev Oncog
, vol.17
, pp. 69-95
-
-
Sheppard, K.E.1
Kinross, K.M.2
Solomon, B.3
Pearson, R.B.4
Phillips, W.A.5
-
13
-
-
4544343980
-
Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies
-
O.J. Shah, Z. Wang, and T. Hunter Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies Curr Biol 14 2004 1650 1656
-
(2004)
Curr Biol
, vol.14
, pp. 1650-1656
-
-
Shah, O.J.1
Wang, Z.2
Hunter, T.3
-
14
-
-
79851513692
-
Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design
-
H. Cheng, S. Bagrodia, S. Bailey, M. Edwards, J. Hoffman, and Q. Hu Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design Med Chem Commun 1 2010 139 144
-
(2010)
Med Chem Commun
, vol.1
, pp. 139-144
-
-
Cheng, H.1
Bagrodia, S.2
Bailey, S.3
Edwards, M.4
Hoffman, J.5
Hu, Q.6
-
15
-
-
84887990348
-
-
< http://www.clinicaltrials.gov >.
-
-
-
-
16
-
-
77949766280
-
Phase i pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers
-
P.M. LoRusso, S.S. Krishnamurthi, J.J. Rinehart, L.M. Nabell, L. Malburg, and P.B. Chapman Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers Clin Cancer Res 16 2010 1924 1937
-
(2010)
Clin Cancer Res
, vol.16
, pp. 1924-1937
-
-
Lorusso, P.M.1
Krishnamurthi, S.S.2
Rinehart, J.J.3
Nabell, L.M.4
Malburg, L.5
Chapman, P.B.6
-
17
-
-
17144418558
-
Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy
-
E.M. Wallace, J.P. Lyssikatos, T. Yeh, J.D. Winkler, and K. Koch Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy Curr Top Med Chem 5 2005 215 229
-
(2005)
Curr Top Med Chem
, vol.5
, pp. 215-229
-
-
Wallace, E.M.1
Lyssikatos, J.P.2
Yeh, T.3
Winkler, J.D.4
Koch, K.5
-
18
-
-
33847095086
-
Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration
-
A.P. Brown, T.C. Carlson, C.M. Loi, and M.J. Graziano Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration Cancer Chemother Pharmacol 59 2007 671 679
-
(2007)
Cancer Chemother Pharmacol
, vol.59
, pp. 671-679
-
-
Brown, A.P.1
Carlson, T.C.2
Loi, C.M.3
Graziano, M.J.4
-
19
-
-
76549129820
-
Drug combination studies and their synergy quantification using the Chou-Talalay method
-
T.C. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res 70 2010 440 446
-
(2010)
Cancer Res
, vol.70
, pp. 440-446
-
-
Chou, T.C.1
-
20
-
-
18744369640
-
Use of within-array replicate spots for assessing differential expression in microarray experiments
-
G.K. Smyth, J. Michaud, and H.S. Scott Use of within-array replicate spots for assessing differential expression in microarray experiments Bioinformatics 21 2005 2067 2075
-
(2005)
Bioinformatics
, vol.21
, pp. 2067-2075
-
-
Smyth, G.K.1
Michaud, J.2
Scott, H.S.3
-
21
-
-
80051584382
-
In vivo activity of combined PI3K/mTOR and MEK inhibition in a KrasG12D;Pten deletion mouse model of ovarian cancer
-
K.M. Kinross, D.V. Brown, M. Kleinschmidt, S. Jackson, J. Christensen, and C. Cullinane In vivo activity of combined PI3K/mTOR and MEK inhibition in a KrasG12D;Pten deletion mouse model of ovarian cancer Mol Cancer Ther 10 2011 1440 1449
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 1440-1449
-
-
Kinross, K.M.1
Brown, D.V.2
Kleinschmidt, M.3
Jackson, S.4
Christensen, J.5
Cullinane, C.6
-
22
-
-
27344435774
-
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
-
A. Subramanian, P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, and M.A. Gillette Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles Proc Natl Acad Sci U S A 102 2005 15545 15550
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 15545-15550
-
-
Subramanian, A.1
Tamayo, P.2
Mootha, V.K.3
Mukherjee, S.4
Ebert, B.L.5
Gillette, M.A.6
-
23
-
-
68049085887
-
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models
-
K.P. Hoeflich, C. O'Brien, Z. Boyd, G. Cavet, S. Guerrero, and K. Jung In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models Clin Cancer Res 15 2009 4649 4664
-
(2009)
Clin Cancer Res
, vol.15
, pp. 4649-4664
-
-
Hoeflich, K.P.1
O'Brien, C.2
Boyd, Z.3
Cavet, G.4
Guerrero, S.5
Jung, K.6
-
24
-
-
12144287282
-
A genetically defined model for human ovarian cancer
-
J. Liu, G. Yang, J.A. Thompson-Lanza, A. Glassman, K. Hayes, and A. Patterson A genetically defined model for human ovarian cancer Cancer Res 64 2004 1655 1663
-
(2004)
Cancer Res
, vol.64
, pp. 1655-1663
-
-
Liu, J.1
Yang, G.2
Thompson-Lanza, J.A.3
Glassman, A.4
Hayes, K.5
Patterson, A.6
-
25
-
-
11144356304
-
S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway
-
M. Pende, S.H. Um, V. Mieulet, M. Sticker, V.L. Goss, and J. Mestan S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway Mol Cell Biol 24 2004 3112 3124
-
(2004)
Mol Cell Biol
, vol.24
, pp. 3112-3124
-
-
Pende, M.1
Um, S.H.2
Mieulet, V.3
Sticker, M.4
Goss, V.L.5
Mestan, J.6
-
26
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, and S. Gabriel EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
-
27
-
-
51849111524
-
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
-
V. Serra, B. Markman, M. Scaltriti, P.J.A. Eichhorn, V. Valero, and M. Guzman NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations Cancer Res 68 2008 8022 8030
-
(2008)
Cancer Res
, vol.68
, pp. 8022-8030
-
-
Serra, V.1
Markman, B.2
Scaltriti, M.3
Eichhorn, P.J.A.4
Valero, V.5
Guzman, M.6
-
28
-
-
58249120506
-
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance
-
N.T. Ihle, R. Lemos Jr., P. Wipf, A. Yacoub, C. Mitchell, and D. Siwak Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance Cancer Res. 69 2009 143 150
-
(2009)
Cancer Res.
, vol.69
, pp. 143-150
-
-
Ihle, N.T.1
Lemos, Jr.R.2
Wipf, P.3
Yacoub, A.4
Mitchell, C.5
Siwak, D.6
-
29
-
-
52449092107
-
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling
-
Q.B. She, S. Chandarlapaty, Q. Ye, J. Lobo, K.M. Haskell, and K.R. Leander Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling PLoS One 3 2008 e3065
-
(2008)
PLoS One
, vol.3
, pp. 3065
-
-
She, Q.B.1
Chandarlapaty, S.2
Ye, Q.3
Lobo, J.4
Haskell, K.M.5
Leander, K.R.6
-
30
-
-
77953761653
-
Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: In silico and biological evaluations
-
S. Dan, M. Okamura, M. Seki, K. Yamazaki, H. Sugita, and M. Okui Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations Cancer Res 70 2010 4982 4994
-
(2010)
Cancer Res
, vol.70
, pp. 4982-4994
-
-
Dan, S.1
Okamura, M.2
Seki, M.3
Yamazaki, K.4
Sugita, H.5
Okui, M.6
-
31
-
-
77954592048
-
Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines
-
E.B. Garon, R.S. Finn, W. Hosmer, J. Dering, C. Ginther, and S. Adhami Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines Mol Cancer Ther 9 2010 1985 1994
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 1985-1994
-
-
Garon, E.B.1
Finn, R.S.2
Hosmer, W.3
Dering, J.4
Ginther, C.5
Adhami, S.6
-
32
-
-
31144453233
-
BRAF mutation predicts sensitivity to MEK inhibition
-
D.B. Solit, L.A. Garraway, C.A. Pratilas, A. Sawai, G. Getz, and A. Basso BRAF mutation predicts sensitivity to MEK inhibition Nature 439 2006 358 362
-
(2006)
Nature
, vol.439
, pp. 358-362
-
-
Solit, D.B.1
Garraway, L.A.2
Pratilas, C.A.3
Sawai, A.4
Getz, G.5
Basso, A.6
-
33
-
-
66449132288
-
KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer
-
J.J. Yeh, E.D. Routh, T. Rubinas, J. Peacock, T.D. Martin, and X.J. Shen KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer Mol Cancer Ther 8 2009 834 843
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 834-843
-
-
Yeh, J.J.1
Routh, E.D.2
Rubinas, T.3
Peacock, J.4
Martin, T.D.5
Shen, X.J.6
-
34
-
-
57449092484
-
KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
-
N. Nakayama, K. Nakayama, S. Yeasmin, M. Ishibashi, A. Katagiri, and K. Iida KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer Br J Cancer 99 2008 2020 2028
-
(2008)
Br J Cancer
, vol.99
, pp. 2020-2028
-
-
Nakayama, N.1
Nakayama, K.2
Yeasmin, S.3
Ishibashi, M.4
Katagiri, A.5
Iida, K.6
-
35
-
-
51349100763
-
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition
-
N.E. Torbett, A. Luna-Moran, Z.A. Knight, A. Houk, M. Moasser, and W. Weiss A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition Biochem J 415 2008 97 110
-
(2008)
Biochem J
, vol.415
, pp. 97-110
-
-
Torbett, N.E.1
Luna-Moran, A.2
Knight, Z.A.3
Houk, A.4
Moasser, M.5
Weiss, W.6
-
36
-
-
57349194139
-
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
-
J.A. Engelman, L. Chen, X. Tan, K. Crosby, A.R. Guimaraes, and R. Upadhyay Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nat Med 14 2008 1351 1356
-
(2008)
Nat Med
, vol.14
, pp. 1351-1356
-
-
Engelman, J.A.1
Chen, L.2
Tan, X.3
Crosby, K.4
Guimaraes, A.R.5
Upadhyay, R.6
-
37
-
-
84865758081
-
Genomic complexity and AKT dependence in serous ovarian cancer
-
A.J. Hanrahan, N. Schultz, M.L. Westfal, R.A. Sakr, D.D. Giri, and S. Scarperi Genomic complexity and AKT dependence in serous ovarian cancer Cancer Discov 2 2012 56 67
-
(2012)
Cancer Discov
, vol.2
, pp. 56-67
-
-
Hanrahan, A.J.1
Schultz, N.2
Westfal, M.L.3
Sakr, R.A.4
Giri, D.D.5
Scarperi, S.6
-
38
-
-
34248563290
-
The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition
-
S. Meloche, and J. Pouyssegur The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition Oncogene 26 2007 3227 3239
-
(2007)
Oncogene
, vol.26
, pp. 3227-3239
-
-
Meloche, S.1
Pouyssegur, J.2
-
39
-
-
81055149891
-
PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity
-
J. Yuan, P.P. Mehta, M.-J. Yin, S. Sun, A. Zou, and J. Chen PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity Mol Cancer Ther 10 2011 2189 2199
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 2189-2199
-
-
Yuan, J.1
Mehta, P.P.2
Yin, M.-J.3
Sun, S.4
Zou, A.5
Chen, J.6
-
40
-
-
84887991788
-
MTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
-
Rodrik-Outmezguine, and Rosen mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling Cancer Discov 2011 1 13
-
(2011)
Cancer Discov
, pp. 1-13
-
-
Rodrik-Outmezguine1
Rosen2
|